Mbx Biosciences, INC Form 4 insider transactions

Salomon Azoulay, Chief Medical Officer of MBX Biosciences, Inc., sold 370 shares of common stock on August 4, 2026 for $65.77 per share.

John W Smither, Chief Financial Officer of MBX Biosciences, Inc., reported multiple transactions in common stock on August 3, 2026.

Steven L. Hoerter, President and CEO and a Director of MBX Biosciences, Inc., reported multiple transactions in common stock on August 3, 2026.

Director Edward T. Mathers was granted 12,500 stock options in MBX Biosciences, Inc. as part of his compensation package.

Director Ora H. Pescovitz was granted 12,500 stock options in MBX Biosciences, Inc. as part of standard director compensation.

Director Patrick J. Heron was granted 12,500 stock options in MBX Biosciences, Inc. as part of his non-employee director compensation.

Director Laurie Stelzer was granted 12,500 stock options in MBX Biosciences, Inc. as part of standard equity compensation.

Director Steven L. Hoerter was granted 12,500 stock options in MBX Biosciences, Inc. as part of his compensation.

Director Steven Ryder was granted 12,500 stock options in MBX Biosciences, Inc. as part of standard equity compensation.

Director Tiba Aynechi was granted 12,500 stock options in MBX Biosciences, Inc. as part of standard equity compensation.

Salomon Azoulay, Chief Medical Officer of MBX Biosciences, Inc., executed a Rule 10b5-1 trading plan, involving the exercise and sale of company stock options.

Chief Medical Officer Salomon Azoulay sold 231 shares of MBX Biosciences to satisfy tax obligations related to RSU vesting.

MBX Biosciences CEO P. Kent Hawryluk sold 607 shares of common stock to satisfy tax obligations related to the vesting of restricted stock units.

MBX Biosciences, Inc. reports a stock grant to Director Steven L. Hoerter, including restricted stock units and stock options.

Steven L. Hoerter, a Director at MBX Biosciences, Inc., received an equity grant adjusted to comply with the company's compensation policy.

Steven L. Hoerter, a Director at MBX Biosciences, Inc., received a stock option grant with an exercise price of $24.74, vesting over one year.

MBX Biosciences' President and CEO, P. Kent Hawryluk, acquired 18,500 shares of common stock for approximately $525,000, signaling strong confidence in the company.

MBX Biosciences President and CEO P. Kent Hawryluk exercised stock options to acquire 28,768 shares of common stock at $16 per share.

MBX Biosciences' Chief Medical Officer, Salomon Azoulay, received 15,000 restricted stock units and options for 70,000 shares as part of compensation.

MBX Biosciences' Chief Financial Officer, Richard Bartram, was granted 15,000 restricted stock units and options to purchase 70,000 shares of common stock.

MBX Biosciences' President and CEO, P. Kent Hawryluk, was granted 35,250 Restricted Stock Units and options to purchase 164,500 shares of common stock.

MBX Biosciences Director Laurie Stelzer was granted 32,000 stock options with an exercise price of $43.14, vesting over three years.

MBX Biosciences Director Steven L. Hoerter was granted 8,000 stock options with an exercise price of $27.08, vesting over one year from November 6, 2025.

MBX Biosciences Director Steven L. Hoerter was granted 100,000 stock options with an exercise price of $24.74, vesting over one year.

MBX Biosciences President & CEO P. Kent Hawryluk exercised options to acquire 182,859 shares of common stock at $3.25 per share.

MBX Biosciences President & CEO P. Kent Hawryluk acquired 20,000 shares of common stock at an average price of $13.6395.

MBX Biosciences Director Steven L. Hoerter acquired 20,000 shares of common stock indirectly through a trust at a price of $13.2492 per share.

A director and 10% owner of MBX Biosciences, Inc., Patrick J. Heron, along with affiliated entities, acquired 666,666 shares of common stock for $18 per share, totaling nearly $12 million.

Edward T. Mathers, a Director and 10% Owner of MBX Biosciences, Inc., has acquired 16,000 stock options with an exercise price of $11.86, vesting based on continued service.

MBX Biosciences Director Steven L. Hoerter was granted 16,000 stock options with an exercise price of $11.86, vesting fully on the earlier of one year or the next annual meeting.